Comment on 'Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab'

Ann Rheum Dis. 2022 Aug;81(8):e136. doi: 10.1136/annrheumdis-2020-218365. Epub 2020 Jul 31.
No abstract available

Keywords: antirheumatic agents; arthritis, rheumatoid; biological therapy.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Arthritis, Rheumatoid* / chemically induced
  • Arthritis, Rheumatoid* / drug therapy
  • C-Reactive Protein*
  • Humans

Substances

  • Antibodies, Monoclonal, Humanized
  • C-Reactive Protein
  • tocilizumab